Nuvation Bio Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020. Filed March 11, 2021. The business combination of Panacea Acquisition Corp. and Legacy Nuvation Bio closed on February 10, 2021, after year-end. Accordingly, the audited financial statements in this 10-K are Panacea’s pre-combination statements, not consolidated operating-company statements for Legacy Nuvation Bio.
Business context and pipeline
Nuvation Bio is a clinical-stage oncology biopharmaceutical company developing small-molecule drug candidates and a Drug-Drug Conjugate (DDC) platform. At year-end, its lead candidate, NUV-422, had entered a Phase 1/2 trial for high-grade gliomas; its other described programs were preclinical. The company reported no product revenue and had not commercialized a product.
Financial position and results
| Metric | Filing disclosure |
|---|---|
| Panacea revenue | None; it had not commenced operating activities before the business combination. |
| Panacea results, inception to December 31, 2020 | General and administrative expenses of $3.061 million; interest income of $7,011; net loss of $3.054 million. Basic and diluted loss per non-redeemable share was $0.80. |
| Panacea cash flows | Operating cash used: $700,826. Investing cash used: $143.750 million, principally for the trust account. Financing cash provided: $145.359 million. Year-end cash outside the trust account: $908,111. |
| Panacea year-end balance sheet | Total assets of $145.004 million, including $143.757 million in trust-account investments; liabilities of $2.799 million; and stockholders’ equity of $5.000 million. Class A shares subject to possible redemption were presented as $137.205 million of temporary equity. |
| Debt and liquidity | Panacea reported no long-term debt or working-capital loans outstanding at year-end. It reported no material market or interest-rate risk, citing the short-term Treasury-focused trust investments. |
| Legacy Nuvation Bio disclosures | The risk-factor discussion reports losses of $41.7 million in 2020 and $33.6 million in 2019, and an accumulated deficit of $76.0 million at December 31, 2020. It also cites $215.8 million of cash and investments at that date. These figures are disclosures about Legacy Nuvation Bio; this filing’s audited statements are Panacea’s. |
Margins are not meaningful because the company had no product revenue. Panacea’s 2020 results cover only the period from its April 24, 2020 inception through year-end, so there is no comparable prior-year operating period in these statements. The filing does not provide a clear comparable-period financial-statement presentation for Legacy Nuvation Bio.
Material changes, financing and outlook
- The February 10, 2021 business combination changed Panacea’s name to Nuvation Bio Inc. In connection with closing, the company received approximately $476.6 million from a PIPE and $25.0 million under a forward purchase agreement. Management stated that existing cash, cash equivalents and short-term investments, including PIPE proceeds, were expected to fund operations for at least 12 months after the merger; this was an estimate based on assumptions, not a guarantee.
- Management’s development targets included reporting Phase 1 NUV-422 data in 2022; filing an IND for NUV-868 in the second half of 2021 and starting a Phase 1 trial in the first half of 2022; filing an IND for NUV-569 in the first half of 2022 and starting a Phase 1 trial in the second half of 2022; and nominating DDC clinical candidates in the second half of 2022. The company also anticipated up to five additional IND applications over six years. These are forward-looking plans, not assured guidance.
- Key risks include clinical and regulatory failure or delay, the unproven DDC approach, continued losses and future capital needs, reliance on third-party research, clinical-trial and manufacturing providers, potential COVID-19 disruption, competition, intellectual-property challenges, and the absence of commercial infrastructure. The filing also highlights concentrated voting control through the dual-class structure and CEO David Hung’s Class B shares.
- The company reported no material legal proceedings. Panacea’s general and administrative costs included public-company, reporting, accounting, audit and transaction-related expenses.
Most important facts for investors to verify
- Confirm that the audited 2020 financial statements are Panacea’s SPAC statements and assess Legacy Nuvation Bio’s financial disclosures separately.
- Reconcile Legacy’s reported year-end $215.8 million of cash and investments with cash available after the merger, transaction costs, redemptions and planned development spending.
- Track NUV-422 trial enrollment, safety, dose selection and data timing, and test whether the other pipeline and IND milestones remain achievable.
- Assess expected cash burn, funding runway and potential dilution against clinical and operating plans.
- Evaluate third-party manufacturing and research dependencies, patent coverage, COVID-related operational exposure, and the implications of founder voting control.